Law firms Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business · 6 October 2016 · 1 min read Corporate and M&A Deal watch Linklaters Pinsent Masons Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryLatham and Paul Weiss among eight new winners as EQT finalises panelIn-HouseWill Lewallen19 Aug 2026Pinsents PEP drops 7.2% after ‘bumper year of investments’Law firmsWill Lewallen19 Aug 2026Linklaters and Winston Taylor bag lead roles on Harvey Nichols rescue dealLaw firmsEliza Winter14 Aug 2026US trio lead on multibillion-dollar Stripe-OpenRouter dealLaw firmsKate Peacock20 Aug 2026International trio serve up as BuzzBallz owner Sazerac buys Au Vodka for £500mLaw firmsEliza Winter18 Aug 2026Latham, A&O Shearman and CC up front as Jeff Bezos-backed consortium buys stake in Liverpool FCLaw firmsKate Peacock14 Aug 2026Dealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealLaw firmsAlex Ryan15 Jan 2024Dealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanLaw firmsAlex Ryan8 Dec 2023Deal Watch: activity powers on as Latham and A&O lead on $19bn energy joint ventureLaw firmsMegan Mayers9 Sep 2022